DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Subcutaneous Progesterone Versus Vaginal Progesterone for Endometrial Preparation in Fresh Donated Oocytes Recipients

Information source: Instituto Bernabeu
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: subcutaneous progesterone (Drug); vaginal progesterone (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Instituto Bernabeu

Official(s) and/or principal investigator(s):
Joanquin Llacer, Ph, Principal Investigator, Affiliation: Instituto Bernabeu

Overall contact:
Joanquin Llacer, Ph, Phone: +34 965 154 000, Email: jllacer@institutobernabeu.com


Randomised, prospective, investigator-blinded, controlled, single-centre study to assess the impact on the ongoing pregnancy rate with the use of two progesterones with different administration routes, in recipients of fresh embryos from donor oocytes, undergoing endometrial preparation for fresh embryo transfer.

Clinical Details

Official title: Subcutaneous Progesterone (Prolutex) Versus Vaginal Progesterone Capsules (Progeffik) for Endometrial Preparation in Fresh Donated Oocytes Recipients: a Randomised, Prospective, Single-blind, Pilot Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: ongoing pregnancy rate at 12 weeks gestation

Secondary outcome:

progesterone level on the days of the transfer

progesterone level on biochemical pregnancy test beta-hCG

endometrium thickness on the day of oocyte retrieval

endometrium thickness on the day of embryo transfer

endometrium morphology on the day of oocyte retrieval

endometrium morphology on the day of embryo transfer

implantation rate

positive biochemical pregnancy test beta- hCG rate

clinical pregnancy rate

miscarriage rate

occurrence of side effects

comfort in relation to the progesterone administration route

Detailed description: Exploratory study with a control group treated according to our Service's usual therapeutic regimen for the transfer of embryos with donor oocytes. The controlled ovarian stimulation protocol in oocyte donors is always calculated according to the standard protocol at the Bernabeu Institute. Endometrial preparation will be carried out following the standard protocol of the Bernabeu Institute as follows: the oestrogen will be administered transdermally and patients with maintained ovarian function undergo medical hypophysectomy with depot GnRH agonists administered in the mid-luteal phase of the previous cycle. On the day of oocyte retrieval, the patient will be randomised: Group A will be administered subcutaneous progesterone 25 mg/day (Prolutex), and Group B will be administered vaginal progesterone in capsules 200 mg/3 times a day (Progeffik). The embryo transfer will be performed on day 5 of the embryo culture (Day +5). A biochemical pregnancy test beta- hCG and the P4 analysis will be performed 14 days after oocyte retrieval. All the cycles will be monitored according to the Department's standard criteria, using transvaginal ultrasound to assess embryonic development and endometrial thickness, as well as analytical controls. The study will be blinded to the investigator. The evaluating professionals will not know if the subject has been administered vaginal progesterone or subcutaneous progesterone. The medication will be delivered by a person who does not participate in the evaluations and who is dedicated to group assignment, to data centralisation, and to delivering the medication. The aim of this study is to determine if the ongoing pregnancy rate in patients undergoing a fresh embryo transfer cycle with donor oocytes is affected by the progesterone administration route.


Minimum age: 18 Years. Maximum age: 48 Years. Gender(s): Female.


Inclusion Criteria:

- Female, aged from 18 to 49 years (both inclusive)

- Woman who wishes to become pregnant

- Endometrial thickness greater 7 mm on the day of patient randomisation to one of the

progesterone groups

- Six or more donor retrieved oocytes

- Patient programmed for fresh embryo transfer on day +5 of embryo culture

- BMI lower than 30 Kg/m2

- Infertility that justifies treatment with donor oocytes

- Male with no known karyotype alterations

- Semen by ejaculation from either the partner or from a bank

- Uterus able to support embryo implantation and pregnancy

- Absence of pregnancy before starting the embryo transfer cycle

- Has given prior written consent

Exclusion Criteria:

- - Important systemic diseases, endocrine-metabolic abnormalities involving the

pituitary, thyroid, adrenals, pancreas, liver or kidney.

- HIV, HBV or HCV seropositivity

- Undiagnosed vaginal bleeding

- Pregnancy, breastfeeding or any contraindication to becoming pregnant

- Malformation of sexual organs incompatible with pregnancy

- Known allergy to progesterone preparations or their excipients

- Current dependence on alcohol, drugs or psychotropic medication

- Concurrent participation in another study

- Concomitant medication that could interfere with the study medication: different

hormonal treatments used in the study, except thyroid hormones, antipsychotics, anxiolytics, hypnotics, sedatives, chronic treatment with prostaglandin inhibitors

Locations and Contacts

Joanquin Llacer, Ph, Phone: +34 965 154 000, Email: jllacer@institutobernabeu.com

Instituto Bernabeu, Alicante 03016, Spain; Recruiting
Joaquin Llacer, Ph, Phone: +34 965 15 40 00, Email: jllacer@institutobernabeu.com
Eva MÂȘ Garcia, Phone: +34 965 15 40 00, Email: evagarcia@institutobernabeu.com
Additional Information

Starting date: March 2015
Last updated: May 4, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017